DELGOCITINIB cream significantly improved quality of life in adults with moderate to severe Chronic Hand Eczema (CHE) in pooled phase III trial data.
Delgocitinib Cream Demonstrates HRQoL Improvements
CHE is a multifactorial inflammatory condition affecting the hands and wrists that can substantially impair health related quality of life (HRQoL). The disease is often characterized by fluctuating symptoms, such as inflammation, irritation, and other limitations that negatively interfere with everyday tasks and social interactions.
Study Aim and Design
To evaluate treatment impact on patient reported outcomes, investigators pooled data from two phase III trials to assess the efficacy of delgocitinib cream. The trials used, DELTA 1 and DELTA 2, were randomized, double-blind, parallel-group identical studies that included adults with moderate-to-severe CHE.
Participants were randomized 1:2 to receive either delgocitinib cream at 20 mg/g or a cream vehicle once daily for 16 weeks, with the primary aim of assessing whether delgocitinib improves HRQoL relative to the vehicle.
A total of 960 participants were included across the two trials, with 639 patients receiving delgocitinib cream and 321 receiving the cream vehicle. Investigators assessed treatment effects using several validated patients reported outcome measures, including the EQ 5D, Dermatology Life Quality Index (DLQI), and Hand Eczema Impact Scale (HEIS).
Patient Reported Outcomes Highlight Treatment Impact
At week 16, delgocitinib cream produced significantly greater improvements in HRQoL versus the vehicle. Across measures, participants receiving delgocitinib showed improvements in overall HRQoL and in specific domains such as daily activity limitations and condition-related embarrassment. Additionally, patients on delgocitinib spent more time in an improved quality-of-life state compared with those on the vehicle.
CHE often imposes both functional and psychological burdens on patients, making patient reported outcome measures particularly relevant in evaluating therapeutic benefit. Investigators concluded that treatment with delgocitinib cream produced clinically significant improvements in health-related quality of life compared with the cream vehicle over the 16-week study period.
Reference
Bauer A et al. Effect of Delgocitinib Cream on Health-Related Quality of Life in Patients With Moderate to Severe Chronic Hand Eczema. Contact Dermatitis.2026;DOI: 10.1111/cod.70114.
Featured Image: InfiniteStudio on Adobe Stock.
